Instinct Bio Completes Business Combination with Relativity Acquisition Corp. and Makes Its Nasdaq Debut Under the Ticker “BIOT” on July 24, 2026

In this episode of Global Economic Press, Alex Brady discusses the recent business combination between Instinct Bio and Relativity Acquisition Corporation, marking Instinct Bio's debut on the Nasdaq Stock Market under the ticker "BIOT" on July 24, 2026. This significant development positions Instinct Bio as a publicly listed life sciences company, offering United States investors a unique opportunity to engage with the transformative field of regenerative medicine and longevity. The podcast explores the implications of this milestone for the healthcare industry and the future of healthcare innovation, highlighting Instinct Bio's integrated approach to stem cell technology, in-house manufacturing, and premium consumer brands. Instinct Bio's entry into the Nasdaq comes at a pivotal moment for the global longevity and wellness market, which is projected to grow significantly over the next decade. The company is strategically positioned to capitalize on this growth with its proprietary stem cell technology and vertically integrated manufacturing capabilities. With operations in Tokyo, Las Vegas, and New York, Instinct Bio offers a differentiated combination of real products, diversified revenue, and a deep innovation pipeline. For more information about Instinct Bio and its groundbreaking work in regenerative medicine, visit their website at https://instinct-biot.com/.